HOT NEWS
Newsfeeds
Roche Media News
Media Releases

Roche Media News
  • Roche with good half year performance
    Group sales up 5% at constant exchange rates, -1% in Swiss francs

  • Roche's investigational medicine cobimetinib, used in combination with Zelboraf (vemurafenib), helped people with advanced melanoma live significantly longer without their disease worsening
    Data from the coBRIM study will be presented at an upcoming medical meeting. Roche plans to submit these data to health authorities around the world. Roche announced today that the Phase III coBRIM study met its primary endpoint. The study demonstrated that the investigational MEK inhibitor cobimetinib, used in combination with Roche’s BRAF inhibitor Zelboraf, helped patients with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer without their disease worsening (progression-free survival; PFS) compared to Zelboraf alone. Adverse events were consistent with those observed in a previous study of the combination.

  • Japan becomes first country to approve Roche's alectinib for people with a specific form of advanced lung cancer
    Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib. Roche today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved alectinib for the treatment of people living with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+). The approval was based on results from a Japanese Phase I/II clinical study (AF-001JP) for people whose tumours were advanced, recurrent or could not be removed completely through surgery (unresectable).

  • Roche announces definitive agreement to acquire Seragon Pharmaceuticals
    Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer. Roche announced today that Genentech, a member of the Roche Group, has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc. (Seragon), a privately held biotechnology company based in San Diego, California, USA. With this acquisition, Genentech obtains rights to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs), for the potential treatment of hormone receptor-positive breast cancer.

  • Roche launches fully automated urine testing analyzer for enhanced result reliability and staff safety
    Roche announced today the launch of cobas 6500, a fully automated urine testing system that consists of two modular analyzers combining urine strip testing and digital urinary microscopy. The system tests for 23 parameters to help diagnose diseases such as urinary tract infection, kidney disease, and diabetes. The cobas 6500 offers the highest throughput on the market, ensures high-quality results and increases laboratory productivity significantly, while reducing manual steps and contamination risks for laboratory staff.

  • CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer
    Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the use of Avastin (bevacizumab) in combination with chemotherapy as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. Ovarian cancer has the highest mortality rate of all gynaecological cancers.1 Of the 230,000 women diagnosed worldwide each year many will have advanced disease that will return after initial treatment.

  • Roche Children's Walk 2014: Roche employees participate in sponsored walk to support vulnerable children in Malawi and around the world
    Today, Roche employees at more than 120 company sites around the world have been showing their solidarity with children in need by raising funds through sponsored walks. The donations will be used to support day-care centers for orphans and educational initiatives in Malawi, as well as children’s charities in their own countries.

  • Roche acquires Genia Technologies to strengthen next generation sequencing pipeline
    Roche announced today the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA. Genia is developing a single-molecule, semiconductor based, DNA sequencing platform using nanopore technology. Under the terms of the agreement, Roche will pay Genia’s shareholders USD 125 million in cash. In addition to this payment from Roche, Genia’s shareholders may receive up to USD 225 million in contingent payments depending on the achievement of certain milestones. Genia’s proprietary technology is expected to reduce the price of sequencing while increasing speed and sensitivity.

  • Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study
    The U.S. Food and Drug Administration (FDA) has granted first Breakthrough Therapy Designation in bladder cancer for MPDL3280A. Roche today announced results from a Phase I open-label study that showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) shrank tumours (overall response rate) in 43 percent (13/30) of people previously treated for metastatic urothelial bladder cancer (UBC) whose tumours were characterised as PD-L1 (Programed Death Ligand-1) positive by a test being developed by Roche. Adverse events (AEs) were consistent with what has been previously reported for MPDL3280A. There were no severe (Grade 4-5) treatment related AEs.

  • CHMP recommends EU approval of Roche’s Gazyvaro for people with chronic lymphocytic leukemia
    Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who have comorbidities making them unsuitable for a certain type of chemotherapy (full-dose fludarabine).